# KZIA catalysts: KAZIA THERAPEUTICS LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kzia/catalysts

> KAZIA THERAPEUTICS LTD (KZIA) has 1 upcoming catalyst. The next is the paxalisib topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KZIA?

KAZIA THERAPEUTICS LTD (KZIA) has 1 upcoming catalyst. The next is the paxalisib topline data readout, early 2027. SEC prospectus (424B): "the anticipated timing of topline data from our Phase 1b trial in advanced triple-negative breast cancer in early 2027 and the expected enrollment of 36 patients in such trial;" [Calendar and source filings](https://sec-api.dev/companies/kzia/catalysts)

Source: SEC prospectus (424B), accession 0001213900-26-095303, https://www.sec.gov/Archives/edgar/data/1075880/000121390026095303/ea0303882-424b5_kazia.htm (retrieved 2026-11-12). Last confirmed 2026-08-31. Cite: https://sec-api.dev/companies/kzia/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | KAZIA THERAPEUTICS LTD |
| Ticker | KZIA (Nasdaq) |
| SEC CIK | 1075880 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/kzia |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2021 | [Paxalisib trial start](https://sec-api.dev/pdufa/paxalisib) | KZIA | newly- diagnosed and recurrent glioblastoma | completed | "In June 2021, the company entered into an agreement with Weill Cornell Medicine for an investigator-initiated phase II clinical trial combining paxalisib with ketogenesis in patients with newly- diagnosed and recurrent glioblastoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1075880/000119312524259805/d872361d20f.htm)) |
| June 5, 2025 | [Paxalisib trial start](https://sec-api.dev/pdufa/paxalisib) | KZIA |  | completed | "Kazia recently announced that the first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with checkpoint inhibitors and chemotherapy in advanced breast cancer, marking a critical step toward clinical translation of these findings." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1075880/000119312525139172/d116207dex991.htm)) |
| early 2027 | [Paxalisib topline data readout](https://sec-api.dev/pdufa/paxalisib) | KZIA |  | scheduled | "the anticipated timing of topline data from our Phase 1b trial in advanced triple-negative breast cancer in early 2027 and the expected enrollment of 36 patients in such trial;" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1075880/000121390026095303/ea0303882-424b5_kazia.htm)) |

## Drugs

- [Paxalisib](https://sec-api.dev/pdufa/paxalisib): newly- diagnosed and recurrent glioblastoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kzia/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KZIA catalysts: KAZIA THERAPEUTICS LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kzia/catalysts

```bibtex
@misc{secapidev_companies_kzia_catalysts_20261116,
  title        = {KZIA catalysts: KAZIA THERAPEUTICS LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kzia/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kzia_catalysts_20261116","title":"KZIA catalysts: KAZIA THERAPEUTICS LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kzia/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
